SCHEMBL2642009

SCHEMBL2642009

CSc1ccc(O)c(C=Cc2ccc(C(=O)O)cn2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.64
MCL1 Q07820 1/20 0.46
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
P4HA1 P13674 2/20 0.37
P4HTM Q9NXG6 2/20 0.37
ERN1 O75460 1/20 0.37
RARA P10276 1/20 0.37
RARB P10826 1/20 0.37
RARG P13631 1/20 0.37
RXRA P19793 1/20 0.37
MIF P14174 1/20 0.36
HCAR3 P49019 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642006 1.00 GCK (0.64) GCKMCL1ALDH1A1CYP1A2CYP2C9
SCHEMBL2642018 0.82 GCK (0.70) GCKALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2642015 0.82 GCK (0.70) GCKALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2398633 0.80 GCK (0.55) GCKALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2398634 0.80 GCK (0.55) GCKALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2642100 0.79 GCK (1.00) GCKHPGDRXRA
SCHEMBL2642055 0.79 GCK (1.00) GCKHPGDRXRA
SCHEMBL2642024 0.75 GCK (0.80) GCKHPGDRXRA
SCHEMBL2642026 0.75 GCK (0.80) GCKHPGDRXRA
SCHEMBL846747 0.69 P4HA1 (0.53) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093535-A1 Vinyl phenyl derivatives as GLK activators ASTRAZENECA AB 2007-04-26 US disclosed
US-7199140-B2 Vinyl phenyl derivatives as GLK activators ASTRAZENECA AB (SE) 2007-04-03 US disclosed
EP-1406620-B1 VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS ASTRAZENECA AB (SE) 2006-11-02 EP disclosed
US-20050054715-A1 Vinyl phenyl derivatives as glk activators ASTRAZENECA AB (SE) 2005-03-10 US disclosed
EP-1406620-A1 VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS Astrazeneca AB (SE) 2004-04-14 EP disclosed
WO-2003000262-A1 VINYL PHENYL DERIVATIVES AS GLK ACTIVATORS ASTRAZENECA AB (SE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054715-A1 Vinyl phenyl derivatives as glk activators GCK, GCKR, GK GCK 1/4885MCL1 2280/4885ALDH1A1 1706/4885
US-20070093535-A1 Vinyl phenyl derivatives as GLK activators GCK, GCKR, GK GCK 1/4885MCL1 2399/4885ALDH1A1 1641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.